FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667097> ?p ?o ?g. }

• W4385667097 endingPage "e010520e" @default.
• W4385667097 startingPage "e010520e" @default.
• W4385667097 abstract "Topic: 3. Acute myeloid leukemia - Biology & Translational Research Background: Acute myeloid leukemia (AML) arises from the somatic acquisition of genetic alterations in hematopoietic progenitor or stem cells. Patients (pts) with favorable or intermediate risk AML, should be cured with pharmacological treatment only; however, over 50% relapse. Unfortunately, genetic factors alone cannot explain this clinical behavior, which is probably due to the persistence of chemo-resistant leukemic stem cells (LSCs) and their interaction with the bone marrow (BM) microenvironment, particularly mesenchymal stem cells (MSCs), which are the most prevalent cell type. Aims: Functionally characterize the MSCs expanded from BM of AML patients to identify mechanisms that may promote treatment resistance/relapse and to establish possible novel prognostic indicators. Methods: We collected BM samples from AML-patients at diagnosis, post-induction, post-consolidation, follow-up, pre-transplant and first relapse. MSCs were expanded from BM-mononuclear cells, obtained by gradient centrifugation, and cultured in Dulbecco’s modified Eagle’s medium, 5% platelet lysate. The medium was changed twice a week, until senescence. AML-MSC morphology, proliferative and differentiation capacity, cell surface antigen expression and reactive oxygen species (ROS) levels were compared with those of healthy donor (HD)-MSCs. Results: So far, we enrolled 29 AML pts. Our subjects were mainly women (72.4%), had a median age of 52 and a performance status of 1. Eight pts had NPM1mut (27%), with 5 of them also harboring FLT3-ITD mutation. Two pts were only FLT3mut (1 ITD and 1 TKD). Four AML-NPM1mut pts achieved complete remission and underwent hematopoietic stem cell transplantation (HSCT); one relapsed 3 months afterwards. Among AML-NPM1wt pts, 19 were treated, 2 died before treatment initiation and 1 relapsed after 9 months. Currently, 15 AML-NPM1wt (71%) and 5 AML-NPM1mut pts (71%) are alive, with a lower overall survival in the AML-NPM1wt cohort (7.63 vs 10.13 months). The results obtained were compared to those observed in MSCs expanded from 20 HDs who underwent BM donation for HSCT. From our preliminary data, acquired at diagnosis, we observed that AML-MSCs showed a lower differentiation capacity, earlier senescence (median passage 4 and 11, respectively) and higher ROS levels than HD-MSCs (median MFI 41 and 13, respectively) (Figure 1). Evaluation of subsequent timepoints to understand the influence of pharmacological treatment on MSC characteristics is currently ongoing. Summary/Conclusion: MSCs interact with LSCs, modifying their proliferation, adhesion properties, quiescence, and clonal expansion; at the same time, LSCs alter the transcriptional program of MSCs, promoting the formation of a “leukemic niche”. Our preliminary data show a decreased differentiation capacity, earlier senescence, and increased ROS production between MSC-AML and MSC-HD, but not between MSCs of AML-NPM1wt and AML-NPM1mut, which represents the most genetically homogeneous subtype. It is known that MSCs interact with LSCs through adhesion molecules and soluble factors, promoting leukemogenesis and chemoresistance and favouring LSCs proliferation and survival. More in detail, AML blasts reduce MSCs antioxidant ability, leading to immune suppression and tumor progression within the BM niche. More analyses are needed to determine whether MSCs of genetically homogeneous subtypes, such as AML-NPM1mut, are involved in treatment resistance/relapse and to identify possible novel disease biomarkers.Keywords: relapsed/refractory, Acute myeloid leukemia, Mesenchymal stem cell" @default.
• W4385667097 created "2023-08-09" @default.
• W4385667097 creator A5006856498 @default.
• W4385667097 creator A5019034145 @default.
• W4385667097 creator A5029420527 @default.
• W4385667097 creator A5040108906 @default.
• W4385667097 creator A5049207898 @default.
• W4385667097 creator A5049398971 @default.
• W4385667097 creator A5050682361 @default.
• W4385667097 creator A5059661425 @default.
• W4385667097 creator A5076431357 @default.
• W4385667097 creator A5078644516 @default.
• W4385667097 creator A5083705281 @default.
• W4385667097 creator A5086927771 @default.
• W4385667097 creator A5092614017 @default.
• W4385667097 date "2023-08-01" @default.
• W4385667097 modified "2023-09-27" @default.
• W4385667097 title "PB1823: THE BONE MARROW MICROENVIRONMENT IN ACUTE MYELOID LEUKEMIA: THE ROLE OF MESENCHYMAL STEM CELLS AND THEIR IMPACT ON THE CLINICAL OUTCOME" @default.
• W4385667097 doi "https://doi.org/10.1097/01.hs9.0000974140.01052.0e" @default.
• W4385667097 hasPublicationYear "2023" @default.
• W4385667097 type Work @default.
• W4385667097 citedByCount "0" @default.
• W4385667097 crossrefType "journal-article" @default.
• W4385667097 hasAuthorship W4385667097A5006856498 @default.
• W4385667097 hasAuthorship W4385667097A5019034145 @default.
• W4385667097 hasAuthorship W4385667097A5029420527 @default.
• W4385667097 hasAuthorship W4385667097A5040108906 @default.
• W4385667097 hasAuthorship W4385667097A5049207898 @default.
• W4385667097 hasAuthorship W4385667097A5049398971 @default.
• W4385667097 hasAuthorship W4385667097A5050682361 @default.
• W4385667097 hasAuthorship W4385667097A5059661425 @default.
• W4385667097 hasAuthorship W4385667097A5076431357 @default.
• W4385667097 hasAuthorship W4385667097A5078644516 @default.
• W4385667097 hasAuthorship W4385667097A5083705281 @default.
• W4385667097 hasAuthorship W4385667097A5086927771 @default.
• W4385667097 hasAuthorship W4385667097A5092614017 @default.
• W4385667097 hasBestOaLocation W43856670971 @default.
• W4385667097 hasConcept C10205521 @default.
• W4385667097 hasConcept C109159458 @default.
• W4385667097 hasConcept C142724271 @default.
• W4385667097 hasConcept C198826908 @default.
• W4385667097 hasConcept C201750760 @default.
• W4385667097 hasConcept C203014093 @default.
• W4385667097 hasConcept C2778461978 @default.
• W4385667097 hasConcept C2778729363 @default.
• W4385667097 hasConcept C2780007613 @default.
• W4385667097 hasConcept C28328180 @default.
• W4385667097 hasConcept C502942594 @default.
• W4385667097 hasConcept C71924100 @default.
• W4385667097 hasConcept C86803240 @default.
• W4385667097 hasConcept C95444343 @default.
• W4385667097 hasConceptScore W4385667097C10205521 @default.
• W4385667097 hasConceptScore W4385667097C109159458 @default.
• W4385667097 hasConceptScore W4385667097C142724271 @default.
• W4385667097 hasConceptScore W4385667097C198826908 @default.
• W4385667097 hasConceptScore W4385667097C201750760 @default.
• W4385667097 hasConceptScore W4385667097C203014093 @default.
• W4385667097 hasConceptScore W4385667097C2778461978 @default.
• W4385667097 hasConceptScore W4385667097C2778729363 @default.
• W4385667097 hasConceptScore W4385667097C2780007613 @default.
• W4385667097 hasConceptScore W4385667097C28328180 @default.
• W4385667097 hasConceptScore W4385667097C502942594 @default.
• W4385667097 hasConceptScore W4385667097C71924100 @default.
• W4385667097 hasConceptScore W4385667097C86803240 @default.
• W4385667097 hasConceptScore W4385667097C95444343 @default.
• W4385667097 hasIssue "S3" @default.
• W4385667097 hasLocation W43856670971 @default.
• W4385667097 hasLocation W43856670972 @default.
• W4385667097 hasOpenAccess W4385667097 @default.
• W4385667097 hasPrimaryLocation W43856670971 @default.
• W4385667097 hasRelatedWork W1812483684 @default.
• W4385667097 hasRelatedWork W1978598034 @default.
• W4385667097 hasRelatedWork W2063113696 @default.
• W4385667097 hasRelatedWork W2322667139 @default.
• W4385667097 hasRelatedWork W2416649916 @default.
• W4385667097 hasRelatedWork W2516866347 @default.
• W4385667097 hasRelatedWork W2531493050 @default.
• W4385667097 hasRelatedWork W25899969 @default.
• W4385667097 hasRelatedWork W2784395700 @default.
• W4385667097 hasRelatedWork W4376111324 @default.
• W4385667097 hasVolume "7" @default.
• W4385667097 isParatext "false" @default.
• W4385667097 isRetracted "false" @default.
• W4385667097 workType "article" @default.